• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tilray Brands Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    4/17/25 7:42:47 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email
    tlry20220918_8k.htm
    false 0001731348 0001731348 2025-04-17 2025-04-17
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
     
    FORM 8-K
     
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): April 17, 2025
     
     
    Tilray Brands, Inc.
    (Exact name of Registrant as Specified in Its Charter)
     
     
    Delaware
    001-38594
    82-4310622
    (State or Other Jurisdiction
    (Commission File
    (IRS Employer
    of Incorporation)
    Number)
    Identification No.)
         
    265 Talbot Street West,
       
    Leamington, ON
     
    N8H 5L4
    (Address of Principal Executive Offices,
     
    (Zip Code)
     
    (844) 845-7291
     
    Not applicable
    (Former Name or Former Address, if Changed Since Last Report)
     
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading
    Name of each exchange on which registered
     
    Symbol(s)
     
    Common Stock, $0.0001 par
    TLRY
     
    value per share
     
    The Nasdaq Global Select Market
         
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 8.01            Other Events.
     
    On April 17, 2025, Tilray Brands, Inc. (the “Company”) issued a press release announcing its intention to hold a special meeting of stockholders on June 10, 2025 to seek approval of an amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect, at the discretion of the Board of Directors, a reverse stock split of the Company’s common stock.  If approved, the applicable reverse stock split ratio would be not less than one-for-ten and not more than one-for-twenty, with the exact ratio to be set within this range by the Board of Directors. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
     
    Additional Information and Where to Find It
     
    This communication may be deemed to be solicitation material in connection with the proposal to be submitted to the Company’s stockholders at its special meeting seeking approval of an amendment to the Certificate of Incorporation to effect a reverse stock split (the “Reverse Stock Split Proposal”). This press release does not contain all the information that should be considered concerning the Reverse Stock Split Proposal and is not intended to form the basis of any investment decision or any other decision in respect of the Reverse Stock Split Proposal. In connection with the Reverse Stock Split Proposal, the Company plans to file a preliminary proxy statement on Schedule 14A with the SEC. Stockholders and other interested persons are urged to read the preliminary proxy statement and all other relevant documents filed with the SEC, including, once available, the definitive proxy statement, as such documents will contain important information about the Company and the Reverse Stock Split Proposal.
     
    When available, the definitive proxy statement and other relevant materials for the Reverse Stock Split Proposal will be made available to stockholders of the Company as of the record date for the special meeting. Investors and security holders will also be able to obtain the documents (when available) free of charge at the SEC’s website, www.sec.gov, or via the Company’s website, www.tilray.com.
     
    Item 9.01
    Financial Statements and Exhibits.
     
    (d) Exhibits
     
               
    Exhibit No.
    Description of Exhibit
    99.1
    Press Release dated April 17, 2025
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
    Forward Looking Statements
     
    This Current Report on Form 8-K includes “forward-looking statements” under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
    Tilray Brands, Inc.
    Date: April 17, 2025                                                                                     
    By: /s/ Mitchell Gendel
    Name: Mitchell Gendel
    Title: Global General Counsel
     
     
    Get the next $TLRY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    11/1/2021$18.00 → $11.80Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners reiterated coverage on Tilray with a new price target

    Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

    4/5/24 7:39:50 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Tilray with a new price target

    Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

    11/2/22 6:37:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray downgraded by The Benchmark Company with a new price target

    The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00

    7/29/22 7:19:40 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements

    NEW YORK and LEAMINGTON, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today announced that the Company has submitted an application requesting an extension to regain compliance with Nasdaq's listing standards regarding its price per share. The Company is evaluating several options including, but not limited to, a stockholder-approved Reverse Stock Split to address capital structure and maintain adherence to Nasdaq's continued listing requirements. Irwin Simon, Chief Executive Officer, Tilray Brands,

    8/14/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical Cannabis Extracts

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, announced today that its wholly-owned subsidiary, FL Group S.R.L., has entered into a strategic partnership with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. ("Molteni"), an Italian pharmaceutical firm specializing in pain therapies and substance dependence. The partnership is designed to broaden the availability of Tilray Medical cannabis extracts for patients across Italy. M

    8/13/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane's and Happy Flower Brands

    NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format extensions from its brands: Fizzy Jane's and Happy Flower. Fizzy Jane's, the sparkling seltzer line that debuted this spring in Georgia, North Carolina, and South Carolina, is now available in a 10mg HDD9 THC format, enhancing the buzz while keeping the same crisp, fruit-forward refreshment fans love. With 15 calories or fewer per can, Fizzy Jane's seltzers come in three vibrant flavors: Vanilla, Blood Orange, and Lemon Lime. The new 10mg drinks join the original 5mg lineup and are now

    8/12/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    SEC Filings

    View All

    SEC Form 10-K filed by Tilray Brands Inc.

    10-K - Tilray Brands, Inc. (0001731348) (Filer)

    7/28/25 7:22:54 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    7/28/25 4:32:41 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    6/23/25 4:10:42 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 6:52:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 3:12:46 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Simon Irwin D exercised 706,216 shares at a strike of $0.58 and covered exercise/tax liability with 374,295 shares, increasing direct ownership by 7% to 4,826,493 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:07:08 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A exercised 93,928 shares at a strike of $0.58 and covered exercise/tax liability with 49,782 shares, increasing direct ownership by 5% to 920,497 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:42 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Financials

    Live finance-specific insights

    View All

    Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results

    Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company's History International Cannabis Revenue Increased 71% in Q4 and 19% for the Fiscal Year; Canadian Cannabis Remained #1 by Revenue in the Fiscal Year; Global Cannabis Gross Margin Increased by ~700 Basis Points in the Fiscal Year 19% Revenue Growth in Tilray Beverages with $241 Million for the Fiscal Year 9% Revenue Growth in Tilray Wellness with $60 Million for the Fiscal Year Strong Balance Sheet with $256 Million Available in Cash and Marketable Securities; Total Debt Repayments of ~$100 Milli

    7/28/25 4:30:13 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025

    NEW YORK and LEAMINGTON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the fourth quarter and full fiscal year ended May 31, 2025, after market close on Monday, July 28, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time. The webcast can be accessed on the Events & Presentations section of Tilray's Investor Relations websi

    7/9/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Reports Q3 Fiscal 2025 Financial Results

    Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. Distribution of Hemp-Derived THC Drinks Across 10 States, Increases Project 420 Cost Savings Plan to $33 Million Tilray Cannabis Increased Gross Margins by 800 bps, Remains the Leader in Canada by Sales Performance, and Generates Strong Sales Growth in Germany Strengthens Balance Sheet with Convertible Note Reduction of $58 Million and Total Debt Reduction of $71 Million, $248 Million Available in Cash and Marketable Securities NEW Y

    4/8/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    View All

    Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

    ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

    1/23/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

    PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

    10/22/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Breckenridge Brewery Opens New Location in Fort Collins, Colorado

    FORT COLLINS, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a Colorado-based craft brewer with over 30 years of experience brewing approachable, well-balanced beers, announces the opening of its new brewery location in Fort Collins. With doors opening in early August 2024, the new 10,000-square-foot Breckenridge Brewery offers a full restaurant experience and a new vibrant atmosphere in the heart of Fort Collins for all to enjoy. The new location will be a full-service restaurant, upholding the Breckenridge Brewery legacy while ushering in new opportunities for innovation and community collaboration. With a menu boasting a diverse range of culinary delights designed to co

    8/5/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

    SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

    2/13/23 1:34:44 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Tilray Brands Inc.

    SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

    2/10/23 4:41:36 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Tilray Brands Inc.

    SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

    7/22/22 4:30:22 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care